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Michael S. Mulligan, MD
Objective: Inhibition of cytokines offers modest protection from injury in animal
models of lung ischemia–reperfusion. Improved strategies would selectively inhibit
the transcriptional activation response to oxidative stress. Mitogen-activated protein
kinases (p38, c-jun N-terminal kinase, extracellular signal–regulated kinase) have
been shown to be activated after oxidative stress and in animal models of acute inflam-
matory lung injury. We hypothesized that mitogen-activated protein kinase inhibition
would block downstream transcriptional activation, providing robust protection from
lung ischemia–reperfusion injury.
Methods: Experimental rats received inhibitors of p38, c-jun kinase, or extracellular
signal–regulated kinase before in situ left lung ischemia–reperfusion. Immunohisto-
chemistry localized cellular sites of mitogen-activated protein kinase activation. Sev-
eral markers of lung injury were assessed. Enzyme-linked immunosorbent assay
measured soluble cytokine and chemokine contents. Western blotting assessed mito-
gen-activated protein kinase phosphorylation. Electromobility shift assays measured
transcription factor nuclear translocation.
Results: Immunohistochemistry localized p38 and c-jun kinase activations in positive
controls to alveolar macrophages. Extracellular signal–regulated kinase was activated
in endothelial and epithelial cells. Animals treated with p38 or c-jun kinase inhibitor
demonstrated significant reductions in transcription factor activation and markers of
lung injury. Extracellular signal–regulated kinase inhibition was not protective. West-
ern blotting confirmed inhibitor specificity.
Conclusion: Inhibition of p38 and c-jun kinase provided significant protection from
injury. The alveolar macrophage appears to be the key coordinator of injury in re-
sponse to oxidative stress. Therapeutically targeting specific cell population (macro-
phage) responses to oxidative stress has the potential benefit of reducing lung
reperfusion injury severity while leaving host immune responses intact.
A
significant barrier to successful outcomes after lung transplantation is the de-
velopment of lung ischemia–reperfusion injury (LIRI). Clinically known as
primary graft dysfunction, LIRI is thought to affect as many as 25% of recip-
ients.1 LIRI is strongly associated with the warm ischemic phase of implantation and
persists despite improvements in donor management, organ preservation, and postop-
erative recipient care.2,3 LIRI is known to increase both early mortality and contribute
to late graft failure through the development of bronchiolitis obliterans.4,5
LIRI is dependent on the activation of inflammatory signaling cascades within res-
ident cells of the lung. The alveolar macrophage (AM) is a key coordinator of these
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TXAbbreviations and Acronyms
AM 5 alveolar macrophage
AP-1 5 activator protein 1
BSA 5 bovine serum albumin
CINC 5 cytokine-induced neutrophil chemoattractant
DMSO 5 dimethylsulfoxide
ERK1/2 5 extracellular signal–regulated kinase
IL-1b 5 interleukin 1b
JNK 5 c-jun N-terminal kinase
LIRI 5 lung ischemia–reperfusion injury
MAPK 5 mitogen-activated protein kinase
MPO 5 myeloperoxidase
NF-kB 5 nuclear factor kB
PBS 5 phosphate-buffered saline solution
SAPK 5 stress-activated protein kinase
responses.6 The inflammatory responses of other resident cell
types, such as the endothelial and epithelial cells, are likely
amplified by the early secretory products of the AM.7 Inhibi-
tion of individual cytokines and chemokines, such as tumor
necrosis factor a (TNF-a) and interleukin 1b (IL-1b), pro-
vides only modest protection from lung injury in response
to ischemia–reperfusion.7 This is explained by the significant
redundancy in the inflammatory response at the posttran-
scriptional level. Targeted inhibition of pretranscriptional
signaling events would therefore potentially provide more
robust protection from injury.
Transcriptional activation through nuclear factor kB (NF-
kB) and activator protein 1 (AP-1) is centrally important to the
development of lung injury in response to oxidative stress.8,9
It has been suggested that transcription factor activation is
regulated by mitogen-activated protein kinases
(MAPKs).10,11 MAPKs are a group of intracellular signaling
proteins activated by multiple stimuli, including inflamma-
tory cytokines (tumor necrosis factor a), lipopolysaccharide,
radiation, and ischemic injury.12,13 They are highly conserved
serine/threonine kinases that require dual phosphorylation to
become activated.14 Three MAPKs have been characterized
in ischemia reperfusion injury: the two stress-activated pro-
tein kinases (SAPKs), p38 and c-jun N-terminal kinase
(JNK), and extracellular signal–regulated kinase (ERK1/2).
The functional significance of MAPK activation in response
to oxidative stress has been described in various organ sys-
tems, though MAPK roles vary. In the heart, p38 appears to
augment reperfusion injury, whereas ERK1/2 plays a protec-
tive role.15,16 In contrast, both p38 and JNK activation have
been shown to promote liver reperfusion injury.17,18
The potential role of MAPK activation in LIRI has been
examined in several reports. JNK inhibition was found to
reduce AP-1 activation and apoptosis in an ex vivo buffer-
perfused model, whereas the p38 inhibitor FR167653 was
found to be protective when added to cold lung-preservationThe Journal of Thorsolution used in a model of canine single-lung transplanta-
tion.19,20 No studies examining the functional role of
ERK1/2 in LIRI exist to date, though recently both ERK1/
2 and JNK phosphorylation were demonstrated in trans-
planted human lungs.21
Although MAPK activation has been demonstrated in
a variety of vascular beds, including the lung, MAPK differ-
ential roles in mediating injury in response to oxidative stress
are not well understood. This is particularly true in the lung.
In these studies, we determined the functional significance of
MAPK activation in our warm ischemic in vivo model of
LIRI. Furthermore, we determined the specific cellular sites
of activation of each MAPK and elucidated the downstream
transcription factors activated by the MAPKs.
Materials and Methods
Reagents
SP600125 and U0126 were purchased from Sigma-Aldrich
Corporation (St Louis, Mo). SP600125 was solubilized in 3 mL
phosphate-buffered saline solution (PBS) containing 10%
dimethylsulfoxide (DMSO). U0126 was solubilized in 1 mL PBS
containing 1% DMSO. FR167653 was a generous gift from Akira
Shimamoto and was solubilized in 1 mL PBS. All other reagents
were purchased from Sigma-Aldrich unless otherwise noted.
Animal Model
Pathogen-free Long-Evans rats (Harlan Sprague Dawley, Inc, Indi-
anapolis, Ind) weighing between 275 and 300 g were used for all ex-
periments. Approval for all experimental protocols was granted by
the University of Washington Animal Care Committee. All animals
received humane care and treatment in accordance with the ‘‘Guide
for the Care and Use of Laboratory Animals’’ (www.nap.edu/cata
log/5140.html)and the ‘‘Principles of Laboratory Animal Care’’
established by the National Society for Medical Research.
A well-established warm, in situ, ischemia-reperfusion model
was used as previously described.6,7 In brief, rodents were anesthe-
tized with 30 mg intraperitoneal pentobarbital, after which a
14-gauge angiocatheter serving as an endotracheal tube was placed
under direct visual guidance into the trachea through a midline neck
incision. The catheter was secured with a single suture, and the an-
imal was hooked up to a Harvard Rodent Ventilator (Harvard Appa-
ratus, Inc, Holliston, Mass). Ventilator settings were standardized
throughout the experimental protocol, with an inspired oxygen con-
tent of 60%, 2 cm H2O positive end-expiratory pressure, and a respi-
ratory rate of 80 breaths/min. Peak pressures were monitored and did
not exceed 10 cm H2O. With the animal in the right lateral decubitus
position, a left thoracotomy was performed, and the pleural space
was entered sharply through the fifth interspace. The left lung was
mobilized atraumatically, with subsequent sharp division of the in-
ferior pulmonary ligament. After mobilization, 50 units heparin in
a volume of 500 mL was then administered through the penile
vein and allowed to circulate for 5 minutes. A noncrushing clamp
was then placed across the left lung hilum, occluding the pulmonary
artery, pulmonary vein, and main stem bronchus, for 90 minutes.
This period of ischemia and hypoxia was held constant for all exper-
imental groups. At the end of this period, the clamp was removed
and the left lung was allowed to reventilate and reperfuse for 4acic and Cardiovascular Surgery c Volume 135, Number 3 657
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subcutaneously every hour to maintain hydration. At the end of the
reperfusion period, midline laparotomy and sternotomy were per-
formed. Blood samples were taken from the inferior vena cava,
and the animals were killed by aortic transection. The heart–lung
block was excised, and the pulmonary circulation was flushed
with 20 mL saline solution. The left lung was then separated from
other mediastinal structures.
Six experimental groups of animals were studied. The negative
control group did not undergo surgical manipulation. The positive
control group received PBS vehicle only, either with or without
DMSO, 45 minutes before left hilar occlusion and subsequently un-
derwent the full ischemia–reperfusion protocol. Vehicle was admin-
istered in the equivalent volume with equivalent percentage DMSO
concentration by the same route as described previously for each in-
hibitor. Each of the three remaining groups was allocated to receive
one of the specific MAPK inhibitors 45 minutes before the onset of
ischemia; all three groups were then subjected to the ischemia–re-
perfusion protocol of 90 minutes of ischemia followed by up to
4 hours of reperfusion. Dosages for all three pharmacologic inhibi-
tors were determined with dose-response curves and Western blot-
ting of injured lung specimens for the phosphorylated MAPKs.
For each inhibitor, the most suppressive dose for each targeted
MAPK without nonspecific inhibition of other MAPKs was used.
FR167653, a specific p38 inhibitor, was given intravenously at
a dose of 6 mg/kg. JNK inhibition was achieved with SP600125
given through the intraperitoneal route at a dose of 25 mg/kg.
U0126, an ERK1/2 inhibitor, was administered intravenously at
200 mg/kg. Lung injury and molecular analysis of tissue samples
were determined with the following protocols.
Immunohistochemical Examination
Whole left lung specimens subjected to 90 minutes of ischemia fol-
lowed by 15 minutes of reperfusion were prepared for immunohis-
tochemical analysis as previously described.7,9 In brief, left lung
tissue specimens were fixed in 10% formalin. Samples were dehy-
drated through graded alcohol baths and embedded in paraffin.
Specimens were cut in 5-mm sections, baked overnight at 50C,
and rehydrated through graded baths to a final distilled water
wash. Specimens were blocked with 5% serum for 30 minutes at
room temperature. Primary antibodies for the phosphorylated
MAPK isoforms (Cell Signaling Technology, Inc, Beverly, Mass)
were applied, and specimens were incubated overnight at 4C. After
primary antibody incubation, manufacturer stock secondary anti-
body (Cell Signaling Technology) was applied and incubated at
room temperature for 30 minutes. After the secondary antibody
incubation, avidin–biotin–peroxidase complex conjugate (Vector
Laboratories, Inc, Burlingame, Calif) was applied. DAB reagent
was then applied, and the sections were developed. Sections were
rinsed in running tap water for 10 minutes, dehydrated, cleared,
and mounted with permanent mounting media. Stained sections
were examined with the image analysis software Image Pro Plus
(Media Cybernetics, LP, Silver Spring, Md).
Lung Permeability Index
Changes in lung vascular permeability were assessed as a ratio of io-
dine 125–radiolabeled bovine serum albumin (125I-BSA) in the left
lung to that of 1 mL of blood. 125I-BSA was purchased from NEN658 The Journal of Thoracic and Cardiovascular Surgery c MarLife Science Products, Inc (Boston, Mass) and was serially diluted
to obtain an activity of approximately 800,000 cpm. A 1% BSA/
PBS solution was added to make a final volume of 500 mL, which
was injected intravenously 5 minutes before removal of the left hilar
clamp. The lung was allowed to reperfuse for 4 hours. Immediately
before the animals was killed, 1 mL blood was aspirated from the
inferior vena cava. The left lung was subsequently harvested as de-
scribed previously. The activities for the left lung and the blood were
then quantified in a gamma counter. The permeability index was
then calculated as follows: Permeability index 5 left lung activity
(in cpm)/1 mL blood activity (in cpm). This ratio corrected for
any variation in the systemic distribution of 125I-BSA.
Myeloperoxidase Assay
Left lung neutrophil accumulation was measured after 4 hours of re-
perfusion by determining myeloperoxidase (MPO) content in lung
specimens as previous described.6,7,9 Lung specimens were homog-
enized for 1 minute in a solution of 0.5% hexadecyltrimethylammo-
nium bromide and 5-mmol/L EDTA in 50-mmol/L potassium
phosphate buffer (pH 6.0). Samples were then sonicated in three
15-second bursts. Samples were centrifuged at 3000g for 30 minutes
at 4C, and the supernatants were recovered. The change in absor-
bance over 1 minute at 460-nm wavelength was recorded after mix-
ing 50 mL of each sample with 1.45 ml of assay buffer (0.0005%
hydrogen peroxide and 0.167-mol/L O-dianisidine dihydrochloride
in 100-mmol/L potassium phosphate buffer, pH 6.0).
Bronchoalveolar Lavage and Inflammatory
Cell Counts
After 4 hours of reperfusion, the left lung was selectively lavaged
with 5 mL sterile saline solution through the endotracheal tube. A
clamp was placed across the right hilum to achieve selective left
lung lavage. The recovered lavage fluid was centrifuged at 1800
rpm for 10 minutes at 4C to pellet the cells. The supernatant was
frozen at280C for later cytokine analysis, and the pellet was resus-
pended in 10 mL sterile PBS. A 1-mL portion of resuspended cells
was subsequently stained with Gill solution and counted with a
hemacytometer (Hausser Scientific, Horsham, Pa). Differential
cell counts were not performed, because previous work has found
nearly all cells to be neutrophils.
Western Blot Analysis
After 15 minutes of reperfusion, total protein was harvested from
whole left lung samples as previously described.7 Protein concentra-
tions from each harvest were quantitated with the bicinchoninic
assay (Thermo Fisher Scientific, Inc, Waltham, Mass). Protein sam-
ples (60 mg) were loaded on 12% sodium dodecylsulfate-polyacryl-
amide gels and electrophoresed at 90 V for 1 to 2 hours. After
transfer to a polyvinylidene difluoride membrane, the membranes
were incubated overnight either with anti–total p38, JNK, or
ERK1/2, or with anti–phosphorylated p38, JNK, or ERK1/2 (Cell
Signaling Technology, Inc, Beverly, Mass). A horseradish peroxi-
dase–conjugated secondary antibody was applied for 1 hour, and
the proteins were subsequently visualized with Pierce Supersignal
Reagents (Thermo Fisher Scientific) and autoradiography. Densi-
tometry was performed to assess relative differences in activation
between groups with Image J software (version 1.2; Media Cyber-
netics, Inc, Silver Spring, Md).ch 2008
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Whole lung samples allowed to reperfuse for 15 minutes had
nuclear protein harvested as previously described.6,9 Protein con-
centrations were again determined with the bicinchoninic assay.
A 5-mg sample of nuclear protein was incubated with biotin-
labeled NF-kB or AP-1 oligonucleotide probe (Panomics, Inc, Fre-
mont, Calif) for 20 minutes at room temperature. Running unla-
beled probe in a cold competition reaction allowed assessment of
the specificity of each probe. Samples were resolved on a 6% do-
decylsulfate-polyacrylamide gel run at 80 V for 1 to 2 hours. After
transfer to a nylon membrane (Amersham Biosciences, Piscataway,
NJ), membranes were incubated for 15 minutes in a streptavidin–
horseradish peroxidase conjugate solution and subsequently visual-
ized with Pierce Enhancer Solution (Thermo Fisher Scientific) and
autoradiography. Densitometry was performed as described previ-
ously.
Enzyme-Linked Immunosorbent Assay
IL-1b and cytokine-induced neutrophil chemoattractant (CINC)
concentrations were analyzed in recovered bronchoalveolar lavage
fluid with sandwich enzyme-linked immunosorbent assays as previ-
ously described (R&D Systems, Minneapolis, Minn).6,9
Statistical Analysis
All data are presented as mean6 SEM unless otherwise designated.
Statistical differences between groups were assessed with the 2-
tailed Student t test (Microsoft Excel 2002; Microsoft Corporation,
Redmond, Wash), with post hoc Bonferroni adjustment for multiple
comparisons. P values refer to comparisons between vehicle-treated




Immunohistochemical examination of left lung specimens
localized cell-specific sites of MAPK phosphorylation
(Figure 1). Unmanipulated negative control animals demon-
strated no staining for the phosphorylated isoforms of theThe Journal of ThorMAPKs. Vehicle-treated positive control animals showed
marked staining for both phosphorylated p38 and JNK,
which localized exclusively to the AM. Conversely, phos-
phorylated ERK1/2 was evident only in the endothelial and
epithelial cells of positive control lungs.
Figure 1. Electromobility shift assay for activator protein 1. Vehi-
cle-treated positive control animals (phosphate-buffered saline
solution lane 3, phosphate-buffered saline solution plus dimethyl-
sulfoxide lane 4) exhibited marked activator protein 1 nuclear
translocation relative to negative control animals (lane 2). Activa-
tor protein 1 translocation was decreased significantly with p38
inhibition (lanes 5 and 6, p 5 .03) and c-jun N-terminal kinase in-
hibition (lanes 7 and 8, p 5 .008). Cold competition lane (lane 1)
verified band as activator protein 1.TXFigure 2. Western blots for phosphorylated p38
(p-p38), c-jun N-terminal kinase (pJNK), and
extracellular signal–regulated kinase (pERK1/2)
demonstrating inhibitor specificity. Target mito-
gen-activated protein kinases for each inhibitor
are indicated with heavy outlines. Specific p38,
c-jun N-terminal kinase, and extracellular sig-
nal–regulated kinase inhibitions were achieved
with FR167653 (FR, 6 mg/kg), SP600125 (SP, 25
mg/kg), and U0126 (U0, 200 mg/kg), respectively,
after 90 minutes of ischemia and 15 minutes of
reperfusion (IR 15).acic and Cardiovascular Surgery c Volume 135, Number 3 659
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TXFigure 3. Immunohistochemical stain-
ing for phosphorylated p38 (A), c-jun
N-terminal kinase (B), and extracellular
signal–regulated kinase (C). Left col-
umn represents lung sections from un-
manipulated negative control animals,
with no staining for any phosphorylated
mitogen-activated protein kinase iso-
forms. Right column represents lung
sections from positive control animals
subjected to 90 minutes of ischemia fol-
lowed by 15 minutes of reperfusion (IR
15). Phosphorylated p38 and c-jun N-
terminal kinase localized exclusively
to alveolar macrophages (thin arrows).
Phosphorylated extracellular signal–
regulated kinase localized to endothe-
lial (thick outline arrow) and epithelial
cells (thick dark arrow).MAPK Phosphorylation
Western blotting was performed on whole left lung homoge-
nates to detect MAPK phosphorylation patterns. Preliminary
work demonstrated that p38 and JNK phosphorylation
peaked at 15 minutes of reperfusion, with somewhat delayed
ERK1/2 phosphorylation that, although detectable at 15 min-660 The Journal of Thoracic and Cardiovascular Surgery c Mautes of reperfusion, did not peak until 60 minutes of reperfu-
sion. Whereas p38 and JNK phosphorylation did not persist
beyond 1 hour of reperfusion, ERK1/2 phosphorylation
was still evident at 4 hours of reperfusion. Preliminary
work determined appropriate inhibitor dosing to achieve spe-
cific MAPK inhibition (Figure 2). Representative blots forrch 2008







control (n 5 8) FR167653 SP600125 U0126
Permeability index
Value 0.09 6 0.006 0.89 6 0.06 0.42 6 0.05 0.58 6 0.05 0.87 6 0.07
Decrease from positive control (%) 53% 35% NA
P vs positive control .002 .03 ..2
Myeloperoxidase
Value 0.09 6 0.009 0.83 6 0.04 0.46 6 0.02 0.66 60.013 0.76 6 0.06
Decrease from positive control (%) 45% 20% NA
P vs positive control ,.001 .05 .0.2
Bronchoalveolar lavage (3105 cells)
Value 4.5 6 0.5 176 6 10 62 6 7 96 6 5
Decrease from positive control (%) 65% 46%
P vs positive control ,.001 .001
Values are mean 6 SEM. NA, Not applicable.TXphosphorylated p38, JNK, and ERK1/2 for control and
treated animals are shown (Figure 3), demonstrating the
degree of inhibitor efficacy for each targeted MAPK.
Markers of left lung injury, including permeability index,
MPO content, and bronchoalveolar lavage cell counts, are
summarized in Table 1. Across all markers of lung injury,
no difference was detected for PBS-treated positive control
samples compared with PBS and DMSO—treated positive
control samples, thus all control animals were pooled for com-
parisons with the individual MAPK inhibitor–treated animals.
Permeability Index
Vehicle-treated positive control animals had a significantly
increased permeability index relative to negative control an-
imals, demonstrating a nearly 10-fold increase (P , .001).
FR167653 (p38 inhibitor) and SP600125 (JNK inhibitor)
decreased the permeability index by 53% and 35%, re-
spectively, both of which were statistically significantly dif-
ferent from positive control animals. ERK1/2 inhibition
with U0126 did not decrease left lung vascular permeability.
MPO Content
Negative control animals had an MPO content of 0.09 6
0.009. This was significantly increased among vehicle-
treated positive control animals after 4 hours of reperfusion
(P , .001). Both p38 and JNK inhibitions showed signifi-
cantly decreased left lung MPO content relative to positive
control animals. Conversely, MPO content was not signifi-
cantly reduced by ERK1/2 inhibition. Although U0126 has
been shown to inhibit ERK1/2 phosphorylation (Figure 2),
it was not functionally protective in our model of LIRI;
further animal studies with U0126 were therefore not
performed.The Journal of ThorBronchoalveolar Lavage Inflammatory Cell Counts
Positive control animals had significantly more inflammatory
cells in bronchoalveolar lavage fluid than did negative con-
trol animals (P , .001). FR167653-treated animals had
65% fewer inflammatory cells than did positive control ani-
mals, whereas SP600125 treatment reduced inflammatory
cell counts by 46%.
Transcription Factor Nuclear Translocation
Electrophoretic mobility shift assays for NF-kB and AP-1
were performed after 15 minutes of reperfusion to detect
the nuclear translocation of these relevant transcription fac-
tors. Representative shift assays are shown for NF-kB (Fig-
ure 4) and AP-1 (Figure 5). Both p38 and JNK inhibitions
significantly limited the nuclear translocation of each tran-
scription factor.
Left Lung Bronchoalveolar Lavage Cytokine/
Chemokine Content
Table 2 demonstrates the concentrations of IL-1b and CINC
within the left lung bronchoalveolar lavage, as measured by
enzyme-linked immunosorbent assay. Relative to negative
control animals, positive control animals had significantly
elevated levels of IL-1b and CINC. Treatment with
FR167653 and SP600125 significantly reduced the levels
of both IL-1b and CINC relative to positive control animals
after 4 hours of reperfusion.
Discussion
These studies demonstrate an important functional role for
the SAPKs in our in vivo model of LIRI. Immunohistochem-
ical examination localized SAPK activation exclusively to
AMs. Inhibition of either p38 or JNK led to marked protec-
tion from lung injury, as measured by pulmonary endothelialacic and Cardiovascular Surgery c Volume 135, Number 3 661
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TXcell dysfunction, lung inflammatory cell infiltration, and sol-
uble cytokine production. Amelioration of injury occurred
through a reduction in NF-kB and AP-1 nuclear transloca-
tion, with a subsequent decrease in cytokine production.
We thus have demonstrated that pretranscriptional inhibition
of the inflammatory signaling cascade can reduce lung injury
severity in response to oxidative stress. Conversely, inhibi-
tion of ERK1/2, which was localized to endothelial and epi-
thelial cells but not the AM, was not found to be protective,
suggesting that ERK1/2 does not significantly contribute to
lung injury in our LIRI model. A limitation of this study
was our use of pharmacologic inhibition. Although these
agents provided specific MAPK inhibition, it was unfortu-
nately incomplete. MAPK inhibition occurs in a dose-depen-
dent manner with these agents, but at the escalating doses
necessary to afford more robust inhibition, specificity is
lost. We therefore chose to concentrate on specificity, en-
abling us to determine the contribution of each individual
MAPK to the generation of LIRI. Modest inhibition of the
SAPK clearly reduced the degree of lung injury. Although
we were unable to show protection with ERK1/2 inhibition,
it however remains possible that a greater degree of inhibition
would afford protection.
Figure 4. Electromobility shift assay for nuclear factor kB. Unma-
nipulated negative control animals demonstrated minimal nuclear
translocation (lane 2). After 90 minutes of ischemia and 15 minutes
of reperfusion, vehicle treated-positive control animals (with
phosphate buffered saline solution lane 3, with phosphate-buff-
ered saline solution plus dimethylsulfoxide lane 4) demonstrated
marked translocation of nuclear factor kB. FR167653 (lanes 5 and
6) and SP600125 (lanes 7 and 8) significantly reduced transactiva-
tion of nuclear factor kB relative to that in positive control animals
(FR167653 P5 .02, SP600125 P5 .007). Cold competition lane (lane
1) verified band as nuclear factor kB.662 The Journal of Thoracic and Cardiovascular Surgery c MaCurrently, cold ischemia, although injurious, is modifiable
and is being safely extended with improvements in storage
techniques.22 Warm ischemia, however, is another matter.
Our warm ischemia model recapitulates the most injurious
phase of clinical lung transplantation. The period of lung
implantation leads to the inevitable consequence of warm
atelectatic ischemia, the duration of which correlates with acute
graft dysfunction. Clinically, this injury is manifest within
several hours of lung implantation. Although cold ischemic
Figure 5. Western blots for phosphorylated p38 (A), c-jun N-termi-
nal kinase (B), and extracellular signal–regulated kinase (C). Pos-
itive control animals (phosphate-buffered saline solution in lane 2,
phosphate-buffered saline solution plus dimethylsulfoxide in lane
3) exhibited significantly more mitogen-activated protein kinase
phosphorylation than did unmanipulated negative control animals
(lane 1, p38 P5 .04, c-jun N-terminal kinase P5 .04, extracellular
signal–regulated kinase P 5 .01). FR167653-treated animals (lane
4) demonstrated significantly reduced p38 phosphorylation rela-
tive to positive control animals (P 5 .03), wheras c-jun N-terminal
kinase and extracellular signal–regulated kinase phosphorylation
were unaffected. SP600125 treatment (lane 5) inhibited c-jun N-ter-
minal kinase phosphorylation (P5 .04) and did not significantly re-
duce extracellular signal–regulated kinase or p38 phosphorylation.
Relative to positive control animals, UO126-treated animals (lane
6) showed reduced extracellular signal–regulated kinase phos-
phorylation (P 5 .03) but no significant inhibition of either p38
or c-jun N-terminal kinase.rch 2008







control (n 5 8) FR167653 SP600125
Interleukin 1b (pg/mL)
Value 70.8 6 6.6 561.8 6 118.2 122.5 6 18.5 178.4 6 28.1
Decrease from positive control (%) 78% 68%
P vs positive control .01 .03
Cytokine-induced neutrophil chemoattractant (pg/mL)
Value 42.5 6 13.9 1361.7 6 144 392 6 24 384.7 6 45.4
Decrease from positive control (%) 71% 72%
P vs positive control ,.001 ,.001
Values are mean 6 SEM.TXtransplant models can be used to study the effects of cold ische-
mic storage, they introduce the variables of allogeneic disparity
and technical complications. Our warm hilar occlusion model
is more specific and reliable for the study of mechanisms of
injury related to warm atelectatic ischemia and reperfusion.
Treatment with inhibitors before the onset of ischemia was
used to resemble what would occur in the clinical transplant
setting. Ideally, donors would receive treatment before organ
removal, thus inhibiting SAPK phosphorylation before the
onset of reperfusion. This is important, as we have demon-
strated that SAPK phosphorylation occurs early in reperfu-
sion within the lung. Because the effects of SAPK
inhibition on other organ systems have not been fully eluci-
dated, the intravenous or intraperitoneal administration of
specific inhibitors is as yet not practical in the clinical setting
of multiorgan retrieval. The potential exists, however, for the
development of inhibitors that can be delivered transbron-
chially, limiting systemic absorption and thus unwanted
effects on other organ systems.
The AM has been shown to be a key mediator in multiple
models of acute inflammatory lung injury.23 A central role for
the AM in the development of LIRI was determined from pre-
vious work in our laboratory, which found that AM depletion
with clodronate disodium reduced proinflammatory mediator
secretion and LIRI severity.6 The data from these studies sug-
gest the SAPKs are centrally important in initiating the tran-
scriptional activation of proinflammatory mediators in
response to oxidative stress in AMs. Conversely, modulation
of the inflammatory responses of endothelial and epithelial
cells through ERK1/2 inhibition was not found to reduce
acute LIRI.
The importance of the vascular endothelium in mediating
inflammatory tissue injury is well known. Multiple models
have shown that in response to various stimuli, the endothe-
lium secretes multiple inflammatory mediators, including
chemoattractants and cell adhesion molecules.24,25 Previ-
ously, with an in vitro model of hypoxia and reoxygenation,
we demonstrated significant increases in secretions of CINCThe Journal of Thoand monocyte chemoattractant protein 1 by pulmonary endo-
thelial cells.26 The inflammatory responses of type 2 pneu-
mocytes have also been characterized. In response to
oxidative stress, type 2 cells showed increased CINC, IL-
1b, and monocyte chemoattractant protein 1 secretion after
as long as 6 hours of reperfusion.27 Furthermore, this re-
sponse was found to be dependent on ERK1/2 but not
SAPK. Although oxidative stress directly activates both en-
dothelial and epithelial cells, our current in vivo data indicate
that inflammatory signaling within both cell types is highly
dependent on secondary amplification by soluble mediators
secreted by AMs. This is supported by our finding that
SAPK phosphorylation peaks earlier than does ERK1/2
phosphorylation, suggesting that the initial cell population
in the lung activated in response to oxidative stress consists
of AMs. As such, to obtain durable protection from lung re-
perfusion injury, strategies should focus on the AM, which
appears to be the key effector cell driving the injurious
response to oxidative stress.
This work is the first to describe SAPK involvement in the
AM in response to lung ischemia–reperfusion. It is also
appreciated that SAPK-dependent inflammatory signaling
is also activated in other models of injury to organs other
than lung and injury not related to ischemia–reperfusion,
with activation occurring in response to multiple inflamma-
tory triggers, including oxidative stress, trauma, bacterial
products, and inflammatory cytokines.12,13,28 Ideally, selec-
tive deletion of the SAPK response to oxidative stress would
reduce LIRI severity while leaving their response to other
stimuli intact. This would protect from reperfusion injury
while maintaining host immunity.
In conclusion, p38 and JNK are critically important in
mediating the inflammatory response of the AM to LIRI.
Pretranscriptional inhibition of proinflammatory mediator
production in the AM is vital to limit the secondary amplifi-
cation of both pulmonary endothelial and epithelial re-
sponses. This targeted therapy, aimed at a proximal step in
the signaling cascade, provides more robust protectionracic and Cardiovascular Surgery c Volume 135, Number 3 663
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TXfrom injury than does inhibition of individual cytokines,
which appear to be produced late and display some functional
redundancy. Selective deletion of the SAPK response in the
lung to oxidative stress could provide protection from pri-
mary graft dysfunction. The exclusive expression of SAPK
in the AM (a resident cell) suggests that pretreatment of po-
tential lung donors could be an effective strategy to limit LIRI
clinically.
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Discussion
Dr David A. Fullerton (Denver, Colo). Dr Wolf, I congratulate you
on both a phenomenal presentation and a really superb article. For
those in the audience who do not think about this on a daily basis,
I would like to point out a couple of things. Number one, there is a tre-
mendous amount of important information in your study. Number
two, the techniques and the model that you have used are quite so-
phisticated, so I think you are to be congratulated again on that point.
I learned a couple of things from your study. One is that it is pos-
sible to—well, let me back up and say what I learned is that MAP
kinases are not uniformly distributed among different tissues, and
so I found one of the novel findings in your study to be the dissoci-
ation of P38 and JNK from ERK1/2 in one organ. Of course, as you
highlighted, P38 and JNK are found in the macrophages, whereas
ERK1/2 are found in the endothelial and epithelial cells. That turns
out to be important, because there is a tremendous amount of interest
in the role of the endothelial and epithelial cells in acute lung injury.
This is of course an important form of acute lung injury, and these
two cell lines have kind of heretofore been ignored in the pathogen-
esis of many of these things.
Could you speculate as to whether your findings suggest that
strategies to effect the response of the endothelial and epithelial cells
are really not very important and that all focus should be on the mac-
rophages? Or perhaps different strategies, other than those you stud-
ied, might be effective in addressing the endothelial and epithelial
cells.rch 2008
Wolf et al Cardiothoracic TransplantationDr Wolf. I think that the roles of the endothelial and epithelial
cells in the generation of LIRI are extremely important. Unfortu-
nately, with pharmacologic inhibition in this model, we were not
able to fully suppress ERK1/2 in these cell types because of the col-
lateral effects of higher drug dosing, which would have suppressed
JNK and P38 as well. We are currently starting to examine the role
of targeted molecular deletion in our cell culture model to try and
delineate the cellular signaling mechanisms in response to oxidative
stress within these cell types, and we will try in the future to extrap-
olate these findings to our animal model.
Dr Fullerton. Another question occurred to me. Given the fact
that macrophages are ubiquitous from one organ to the next, and
given the fact that one thing that all solid organ transplants must en-
dure are the injuries of ischemia and reperfusion—and it is thought
of course that macrophages are operative, and I think you have
shown us that in spades—could you speculate a little bit as to
whether not macrophages behave in a similar manner from one or-
gan to the next? For instance, lung versus liver versus heart? Have
your studies addressed any of that?
DrWolf.Our studies did not specifically address the role of mac-
rophages in other organ systems. I think that the Kupffer cell within
the liver probably does have a role similar to that of the AM. They
are both a myeloid-derived lineage. The heart is a little bit tougher to
speculate on, because as far as I know it does not have the same
degree of myeloid-derived cells. I believe that work in one of the
collaborative laboratories at our institution is examining the role
of circulating leukocytes in generating cardiac ischemia–reperfusion
injury.
Unidentified Discussant. I just had one question. It seems that
your model is purely one of warm ischemia. Have you gone further
to simulate a clinical situation of cold ischemia followed by warm
ischemia followed by reperfusion? And have you looked at any ofThe Journal of Thorthe readily available pulmonoplegic solutions to see how that affects
the whole injury phenomenon and your model?
DrWolf. Our goal in this study was to recapitulate what we con-
sider the most injurious phase of the reperfusion injury process, the
warm ischemic period. From my understanding with the new pres-
ervation techniques, we can carry cold ischemia out to about 12
hours. In this study we have not done that because as I stated, we
are most interested in the warm ischemic phase.
Dr David Follette (Sacramento, Calif). This was a great study,
beautifully presented and carried out. As Dr Halloran pointed out
and we have looked at, a major component will be the ischemic
injury to the organ, because that affects how the host immune sys-
tem will approach the organ once it is implanted. As Dr Cohen
pointed out, you have a fairly severe model, because in this
whole area there are three components: what happens either
before or during the ischemic phase, the storage phase, and then
the reperfusion phase. My colleague and our member Dr Ardehali
showed how modification of lung reperfusion can make significant
differences.
Are there ways that this knowledge, which is fantastic, can be
applied before the ischemic phase to give added protection against
ischemia, looking more as you have done at a more molecular
way rather than a global way as we would do with either cardiople-
gia or pulmonoplegia?
Dr Wolf. Unfortunately, I do not think that these specific inhib-
itors would lend themselves to the clinical setting, because they lose
specificity at higher doses. We have recently begun to use short
interfering RNA, which we have found localized exclusively to
the AM within the lung. I think that potentially in the future, if we
can reliably continue to show promise, this technique could provide
clinical benefits. This technology is still in its infancy, however, so
we will have to see where this goes.TX
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